Riskpilot← Back to searchSign inGet full accessMedifemi Oy
OYDissolvedY-tunnus 2011037-0Keltasirkuntie 18-AMedical specialists activities · NACE 8622Est. 2006— employees
Revenue 2025
EUR 198K
+8% vs 2024
EBITDA margin
6.3%
+22% vs 2024
Equity ratio
38.2%
Financial strength
Net profit 2025
EUR 7K
+1295% vs 2024
| Revenue | EUR 198K | +8% |
| EBITDA | EUR 12K | +22% |
| Net profit | EUR 7K | +1295% |
| Total assets | EUR 62K | -96% |
| Equity | EUR 24K | -95% |
| Employees | — | — |
Legal name
Medifemi Oy
Y-tunnus number
2011037-0
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
9. tammikuuta 2006
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-10-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on tuottaa väestölle terveydenhoito- ja lääkäripalveluja. Lisäksi yhtiön toimialaan kuuluu järjestää terveydenhoitoalan koulutusta sekä konsultointia, harjoittaa alan tutkimustoimintaa ja tuottaa ja julkaista kirjallisuutta. Yhtiö voi ostaa, myydä, vuokrata ja omistaa huoneistoja, kiinteistöjä osakkeita sekä muita arvopapereita.
Address
Keltasirkuntie 18-A
Phone
+3580405131442
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 145 | 0 | 143 | 184 | 198 |
| Staff expenses | −66 | −0 | −80 | −92 | −101 |
| EBITDA | 9 | 0 | 0 | 10 | 12 |
| Depreciation & amort. | −0 | −0 | −0 | −12 | −8 |
| EBIT | 9 | 0 | 0 | 0 | 4 |
| Net financials | −0 | 0 | 0 | 5 | 0 |
| Profit before tax | 8 | 0 | 0 | 4 | 4 |
| Tax | 5 | −0 | −0 | −0 | −3 |
| Net profit | 3 | — | 0 | 1 | 7 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 48 | 0 | 202 | 1 742 | 62 |
| Equity | 42 | 0 | 17 | 500 | 24 |
| Long-term debt | 2 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 | 0 | 12 | 47 | 38 |
| Total debt | 6 | 0 | 12 | 47 | 38 |
EBITDA margin
6.3%
This company
15.8%
Market median
-60% vs market
20212025
Equity ratio
38.2%
This company
38.2%
Market median
+0% vs market
20212025
Return on equity
31.6%
This company
18.4%
Market median
+72% vs market
20212025
Net profit margin
3.8%
This company
8.1%
Market median
-53% vs market
20212025
Asset turnover
3.20×
This company
1.12×
Market median
+186% vs market
20212025
Debt / equity
1.62×
This company
0.62×
Market median
-161% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2024-11-01 – 2025-10-31
- Annual report 2024Filed via PRH / YTJ · Period 2023-11-01 – 2024-10-31
- Annual report 2023Filed via PRH / YTJ · Period 2022-11-01 – 2023-10-31
- Annual report 2022Filed via PRH / YTJ · Period 2021-11-01 – 2022-10-31
- Annual report 2021Filed via PRH / YTJ · Period 2020-11-01 – 2021-10-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
TM Audit | Audit | 2025 |
PM Deputy auditor | Deputy auditor | 2025 |
EA Deputy Member | Deputy Member | 2024 |
MH Chief Executive Officer | Chief Executive Officer | 2006 |
| Former (3) | ||
UM Deputy auditor | Deputy auditor | 2006 – 2025 |
RC Deputy Member | Deputy Member | 2006 – 2024 |
| Audit | 2006 – 2025 | |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medifemi Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Timo Matti Kervinen | Audit | 0 companies |
| Ulla Maija Tikkanen | Deputy auditor | 0 companies |
| Richard Carl Philip Creutz | Deputy Member | 0 companies |
| Riitta Tellervo Kallio-Saukkonen | Audit | 0 companies |
| Pirjo Marjatta Saarelainen | Deputy auditor | 0 companies |
| Emil Andreas Erik Creutz | Deputy Member | 0 companies |
| Maria Helena Creutz | Chief Executive Officer | 0 companies |